- World Pharma News Home » Financial » Sandoz receives European Commission approval for biosimilar filgrastim
(a free service delivered by FeedBurner)
Sandoz has received final approval for its third biosimilar, filgrastim, paving the way for this important oncology medicine to be made available to patients across the European Union. Filgrastim is indicated for the treatment of neutropenia, a condition characterized by a lack of neutrophils - one of the most common types of white blood cells - whose role is to fight infection in the body. Neutropenia is often associated with chemotherapy or bone marrow transplants, as well as advanced HIV infections. Filgrastim is a natural protein produced commercially by recombinant DNA technology, which stimulates production of white blood cells.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments